A Phase 3 interventional study of Corticosteroids and Cyclophosphamide in Lupus Nephritis and Systemic Lupus Erythematosus, sponsored by Genentech, Inc.. Terminated. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Nephritis by Hoffmann-La Roche — 2 open to participants now, 3 under way, 1 of them phase 3. Lupus Nephritis · Hoffmann-La Roche.
Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, this one has the largest enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 5th registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →2 of the 11 studies in Lupus Nephritis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Argentina, Brazil, Colombia and 3 more countries
Ages 18+
Hoffmann-La Roche · Sites in United States, Brazil, Canada and 9 more countries
Ages 5–17
By country, each count listing its studies:
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 381 is above the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 52 across the 11 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, randomized, double-blind, placebo-controlled, multicentre, parallel-group study designed to evaluate the efficacy and safety of ocrelizumab added to SOC (corticosteroid plus one of two immunosuppressant regimens) compared with placebo added to SOC in patients with WHO or ISN Class III or IV lupus nephritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Ocrelizumab 400 mg i.v. infusion on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
Drug: Corticosteroids · Drug: Cyclophosphamide · Drug: Mycophenolate Mofetil · Drug: Ocrelizumab · Drug: Azathioprine
Participants received Ocrelizumab 1000 mg i.v. infusion on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
Drug: Corticosteroids · Drug: Cyclophosphamide · Drug: Mycophenolate Mofetil · Drug: Ocrelizumab · Drug: Azathioprine
Participants received placebo i.v. infusion on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks plus SOC regimen.
Drug: Corticosteroids · Drug: Cyclophosphamide · Drug: Mycophenolate Mofetil · Drug: Placebo · Drug: Azathioprine
Intravenous and oral repeating dose
Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
Ocrelizumab was administed at a dose and as per schedule in arm description
Placebo was administered as per schedule in arm description
Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
Number of Participants Who Achieved Complete Renal Response (CRR)
CRR was defined as: 1. Normal serum creatinine (and with no more than a 25 percent \[%\] increase from Baseline); 2. Improvement in urinary protein:urinary creatinine ratio to less than or equal to (≤) 0.5. PRR was defined as at least 50 percent (%) reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was greater than (\>) 3, a urine protein:urine creatinine ratio of less than (\<) 3 needed to be achieved.
Time frame: Week 48
Percentage of Participants Who Achieved Overall Response
Overall response rate (ORR) equals (=) CRR + PRR. CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from baseline) 2. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50 % reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio is \>3, a urine protein:urine creatinine ratio of \<3 needs to be achieved.
Time frame: Week 48
Percentage of Participants Who Achieved a Renal Response (Partial or Complete) by Week 36, and Sustain or Improve This Response Until Week 48
Time frame: Weeks 36, 40, 44, and 48
Time To Complete Renal Response
Time to complete renal response was proposed to be analyzed using a stratified log rank test with race and SOC as stratification factors. Comparisons of ocrelizumab versus placebo were to be expressed as p-values, estimated hazard ratios, adjusted proportions of participants who achieved a complete renal response and their 95% confidence intervals. Kaplan-Meier curves were to be produced. Due to early termination of the study the analyses were not performed.
Time frame: Baseline up to Week 48
Area Under the Curve (AUC) of Calculated Glomerular Filtration Rate (cGFR) Between Baseline and Week 48
The improvement of AUC of cGFR was to be measured between Baseline and Week 48. This was to be analyzed with Analysis of Covariance (ANCOVA) with race and SOC as covariates.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48
Percentage of Participants Who Achieved A Reduction In Systemic Lupus Erythematosis Disease Activity Index (SLEDAI) -2K Score
SLEDAI-2K measures disease activity at the visit or within the preceding 10 days. It comprised of 24 descriptors, covering 9 organ systems, and reflects disease activity over the previous 10 days.The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Time to First Renal Flare In Those Participants Who Demonstrated at Least a Partial Renal Response
Renal flares may be either proteinuric or nephritic as defined below: Proteinuric Flares are defined as follows:In participants who achieve a urine protein:urine creatinine (Upr:Ucr) ≤ 0.5, an increase to Upr:Ucr \>1; In participants with an Upr:Ucr \>0.5, a doubling of Upr:Ucr (with a minimum increase to Upr:Ucr \>2). Nephritic Flare defined as: Increase in serum creatinine of ≥30% from the lowest value achieved in the study accompanied by Increase Upr:Ucr \>1 Or New/worsening active urine sediment on two consecutive occasions, in the absence of urinary tract infection or other causes of hematuria.
Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Percentage of Participants Who Achieved Clinically Meaningful Improvement in the Physical and Mental Component Scores of the Short Form 36 (SF36) From Baseline to Week 48
The SF36 Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions physical role functioning, emotional role functioning, social role functioning, and mental health.
Time frame: Baseline and Weeks 1, 12, 24, 36, and 48
Percentage of Participants Who Achieved Clinically Meaningful Improvement in Fatigue Using the Functional Assessment of Chronic Illness Therapy (Facit) Fatigue Questionnaire From Baseline to Week 48
The FACIT Fatigue Scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued).
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Percentage of Participants Who Achieved Clinically Meaningful Improvement in Pain Using the Modified Brief Pain Inventory Short Form (mBPI-SF) From Baseline to Week 48
m-BPI-sf is a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours with a range of 0 (no pain) to 10 (worst imaginable pain).
Time frame: Baseline and Weeks 1, 12, 24, 36, and 48
Health Care Visits Over the 48-Week Treatment Period
The number of health care visits (including doctor's office visits, Emergency room/ Accident and Emergency \[ER/A\&E\] visits and hospitalizations) over the 48-week treatment period were recorded.
Time frame: Weeks 1, 24, and 48
Percentage of Participants Who Achieved a CRR or PRR And Who Received A Corticosteroid Dose of <10 Milligrams Per Day (mg/Day) From Week 24 to Week 48
CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein:urine creatinine ratio of \<3 needed to be achieved.
Time frame: Week 48
Percentage of Participants Who Achieved a CRR or PRR And Who Received a Corticosteroid Dose of <5 mg/Day by Week 48
CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein: urine creatinine ratio of \<3 needed to be achieved.
Time frame: Week 48
Average Corticosteroid Burden Measured by AUC of the Cumulative Corticosteroid Dose Between 16 and 48 Weeks
AUC is the area under the curve (mathematically known as definite integral) in a plot of concentration of drug in blood plasma against time. AUC was to be used to determine the average corticosteroid burden.
Time frame: Weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48
Percentage of Participants Who Stopped Immunosuppressants After Week 48
The number of participants who stopped immunosuppressants were to be determined by survey.
Time frame: Week 48
Mean Absolute Counts of Cluster of Differentiation (CD) 19 Positive (+) Cells Per Visit
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. CD19+ cells were measured as cells per microliter (cells/uL).
Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Percentage of Participants With CD19+ Absolute B Cell Counts <10 Cells Per Microliter (Cells/uL)
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. 0 represents 0% of participants.
Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Percentage of Participants With CD19+ Absolute B Cell Counts <20 Cells/uL by Visit
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. n = number of participants analyzed at the specified visit. 0 represents 0% of participants.
Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Percentage of Participants With CD19+ Absolute B Cell Counts Less Than the Lower Limit of Normal (LLN) by Visit
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. \<LLN = 80 cells/uL.
Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Percentage of Participants Achieving a Major Clinical Response or a Partial Clinical Response
A major clinical response was defined as British Isles Lupus Assessment Group (BILAG) C scores or better at Week 24 without developing any new A or two new B scores up to Week 24 and maintenance of this response without developing a moderate or severe flare between Week 24 and Week 48. A partial clinical response was defined as BILAG C scores or better at Week 24 and maintaining this response without developing a flare for 16 consecutive weeks. The BILAG is an organ-specific 86-question assessment based on the principle of the doctor's intent to treat, which requires an assessment of improved (1), the same (2), worse (3), or new (4) over the last month. Within each organ system, multiple manifestations and laboratory tests are combined into a single score for that organ. The resulting scores for each organ can be A through E, where A is very active disease, B is moderate activity, C is mild stable disease, D is resolved activity, and E indicates the organ was never involved.
Time frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Screening was done from Day -14 to Day -1.
| Milestone | OCR 400 mg + SOC | OCR 1000 mg + SOC | Placebo + SOC |
|---|---|---|---|
| Started | 127 | 128 | 126 |
| Completed | 83 | 74 | 49 |
| Not completed | 44 | 54 | 77 |
| Withdrew: Did not cooperate | 2 | 6 | 1 |
| Withdrew: Failure to return | 6 | 5 | 6 |
| Withdrew: Adverse event, serious fatal | 3 | 6 | 6 |
| Withdrew: Adverse event | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 17 | 17 | 7 |
| Withdrew: Administrative reasons | 15 | 19 | 55 |
CRR was defined as: 1. Normal serum creatinine (and with no more than a 25 percent \[%\] increase from Baseline); 2. Improvement in urinary protein:urinary creatinine ratio to less than or equal to (≤) 0.5. PRR was defined as at least 50 percent (%) reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was greater than (\>) 3, a urine protein:urine creatinine ratio of less than (\<) 3 needed to be achieved.
| Percentage of Participants | OCR 400 mg + SOC | OCR 1000 mg + SOC | Placebo + SOC |
|---|---|---|---|
| CRR | 42.7 | 31.5 | 34.7 |
| PRR | 24 | 35.6 | 20 |
Overall response rate (ORR) equals (=) CRR + PRR. CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from baseline) 2. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50 % reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio is \>3, a urine protein:urine creatinine ratio of \<3 needs to be achieved.
| Percentage of Participants | OCR 400 mg + SOC | OCR 1000 mg + SOC | Placebo + SOC |
|---|---|---|---|
| Percentage of Participants Who Achieved Overall Response | 66.7 (56 to 77.3) | 67.1 (56.3 to 77.9) | 54.7 (43.4 to 65.9) |
No measurements were reported for this outcome.
Time to complete renal response was proposed to be analyzed using a stratified log rank test with race and SOC as stratification factors. Comparisons of ocrelizumab versus placebo were to be expressed as p-values, estimated hazard ratios, adjusted proportions of participants who achieved a complete renal response and their 95% confidence intervals. Kaplan-Meier curves were to be produced. Due to early termination of the study the analyses were not performed.
No measurements were reported for this outcome.
The improvement of AUC of cGFR was to be measured between Baseline and Week 48. This was to be analyzed with Analysis of Covariance (ANCOVA) with race and SOC as covariates.
No measurements were reported for this outcome.
SLEDAI-2K measures disease activity at the visit or within the preceding 10 days. It comprised of 24 descriptors, covering 9 organ systems, and reflects disease activity over the previous 10 days.The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity
No measurements were reported for this outcome.
Renal flares may be either proteinuric or nephritic as defined below: Proteinuric Flares are defined as follows:In participants who achieve a urine protein:urine creatinine (Upr:Ucr) ≤ 0.5, an increase to Upr:Ucr \>1; In participants with an Upr:Ucr \>0.5, a doubling of Upr:Ucr (with a minimum increase to Upr:Ucr \>2). Nephritic Flare defined as: Increase in serum creatinine of ≥30% from the lowest value achieved in the study accompanied by Increase Upr:Ucr \>1 Or New/worsening active urine sediment on two consecutive occasions, in the absence of urinary tract infection or other causes of hematuria.
No measurements were reported for this outcome.
The SF36 Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions physical role functioning, emotional role functioning, social role functioning, and mental health.
No measurements were reported for this outcome.
The FACIT Fatigue Scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued).
No measurements were reported for this outcome.
m-BPI-sf is a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours with a range of 0 (no pain) to 10 (worst imaginable pain).
No measurements were reported for this outcome.
The number of health care visits (including doctor's office visits, Emergency room/ Accident and Emergency \[ER/A\&E\] visits and hospitalizations) over the 48-week treatment period were recorded.
No measurements were reported for this outcome.
CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein:urine creatinine ratio of \<3 needed to be achieved.
No measurements were reported for this outcome.
CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein: urine creatinine ratio of \<3 needed to be achieved.
No measurements were reported for this outcome.
AUC is the area under the curve (mathematically known as definite integral) in a plot of concentration of drug in blood plasma against time. AUC was to be used to determine the average corticosteroid burden.
No measurements were reported for this outcome.
The number of participants who stopped immunosuppressants were to be determined by survey.
No measurements were reported for this outcome.
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. CD19+ cells were measured as cells per microliter (cells/uL).
| Cells/uL | Placebo + SOC | OCR 400 mg + SOC | OCR 1000 mg + SOC | OCR + SOC | Placebo-Mycophenolate Mofetil (MMF) | Placebo-Euro Lupus (EL) |
|---|---|---|---|---|---|---|
| Baseline | 203.5 ± 191.4 | 256.3 ± 300.2 | 224.1 ± 231.7 | 240.8 ± 268.9 | 213.7 ± 201.7 | 186.3 ± 175 |
| Day 15 | 262.7 ± 273.9 | 1.9 ± 1.9 | 2.2 ± 3.4 | 2 ± 2.7 | 327.4 ± 324.9 | 163.3 ± 115.8 |
| Week 4 | 209.7 ± 221.4 | 1.4 ± 2.5 | 1.3 ± 1.6 | 1.4 ± 2.1 | 253.4 ± 263.9 | 143.3 ± 107.4 |
| Week 16 | 125.9 ± 186.9 | 2.6 ± 3.6 | 2 ± 3.8 | 2.3 ± 3.7 | 154.3 ± 222.2 | 74.7 ± 75.3 |
| Week 32 | 116.6 ± 154.3 | 7.8 ± 25.8 | 2.1 ± 2.7 | 5.1 ± 18.8 | 141.2 ± 172.5 | 68.5 ± 96.8 |
| Week 48 | 110 ± 114.3 | 11.7 ± 43.6 | 2.6 ± 8.9 | 7.3 ± 32.2 | 134.9 ± 123.3 | 61.3 ± 75 |
| Day 1 Pre-infusion | 203.5 ± 191.4 | 256.3 ± 300.2 | 222.8 ± 230.2 | 240 ± 268 | 213.7 ± 201.7 | 186.3 ± 175 |
| Day 1 Post-infusion | 103.1 ± 115.1 | 11.1 ± 28.6 | 5.7 ± 8.5 | 8.4 ± 21.3 | 102.4 ± 114.3 | 104.3 ± 118.6 |
| Day 15 Pre-infusion | 264.4 ± 276.6 | 1.9 ± 1.9 | 2.1 ± 3.3 | 2 ± 2.7 | 322.5 ± 323.5 | 164.5 ± 118 |
| Day 15 Post-infusion | 91.2 ± 109.2 | 1 ± 1.3 | 0.9 ± 1.4 | 0.9 ± 1.3 | 106.3 ± 130.8 | 65.8 ± 50.4 |
| Week 16 Pre-infusion | 127.8 ± 190.1 | 2.5 ± 3.3 | 2.1 ± 3.9 | 2.3 ± 3.6 | 156.5 ± 226.3 | 76.3 ± 76.5 |
| Week 16 Post-infusion | 52.7 ± 72.6 | 1.2 ± 1.6 | 0.8 ± 1 | 1 ± 1.3 | 64.2 ± 83 | 30.9 ± 40.2 |
| Week 32 Pre-infusion | 125 ± 161.1 | 5.1 ± 16.5 | 2 ± 2.7 | 3.6 ± 11.8 | 153.4 ± 180.6 | 72.2 ± 100.4 |
| Week 32 Post-infusion | 46.2 ± 54.4 | 1 ± 1.5 | 0.7 ± 1.4 | 0.9 ± 1.4 | 56.9 ± 62.5 | 27.6 ± 29.5 |
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. 0 represents 0% of participants.
| Percentage of Participants | Placebo + SOC | OCR 400 mg + SOC | OCR 1000 mg + SOC | OCR + SOC | Placebo-Mycophenolate Mofetil (MMF) | Placebo-Euro Lupus (EL) |
|---|---|---|---|---|---|---|
| Baseline | 4.3 | 4.2 | 1.5 | 2.9 | 6.8 | 0 |
| Day 15 | 4.5 | 100 | 97.1 | 98.6 | 7.5 | 0 |
| Week 4 | 4.4 | 98.5 | 100 | 99.3 | 7.3 | 0 |
| Week 16 | 4.3 | 95.8 | 97.1 | 96.5 | 6.7 | 0 |
| Week 32 | 7.4 | 91.8 | 95.6 | 93.6 | 8.9 | 4.3 |
| Week 48 | 5.9 | 88.7 | 98.5 | 93.4 | 4.4 | 8.7 |
| Day 1 Pre-infusion | 4.3 | 4.2 | 1.5 | 2.9 | 6.8 | 0 |
| Day 1 Post-infusion | 10 | 81.2 | 83.8 | 82.5 | 14 | 3.7 |
| Day 15 Pre-infusion | 4.4 | 100 | 97.1 | 98.6 | 7 | 0 |
| Day 15 Post-infusion | 7.5 | 100 | 100 | 100 | 11.9 | 0 |
| Week 16 Pre-infusion | 4.5 | 97 | 97 | 97 | 7 | 0 |
| Week 16 Post-infusion | 11.5 | 100 | 100 | 100 | 12.5 | 9.5 |
| Week 32 Pre-infusion | 3.3 | 93.7 | 95.2 | 94.4 | 5.1 | 0 |
| Week 32 Post-infusion | 15 | 100 | 100 | 100 | 10.5 | 22.7 |
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. n = number of participants analyzed at the specified visit. 0 represents 0% of participants.
| Percentage of Participants | Placebo + SOC | OCR 400 mg + SOC | OCR 1000 mg + SOC | OCR + SOC | Placebo-Mycophenolate Mofetil (MMF) | Placebo-Euro Lupus (EL) |
|---|---|---|---|---|---|---|
| Baseline | 7.1 | 11.3 | 3 | 7.3 | 11.4 | 0 |
| Day 15 | 7.6 | 100 | 98.5 | 99.3 | 10 | 3.8 |
| Week 4 | 10.3 | 100 | 100 | 100 | 12.2 | 7.4 |
| Week 16 | 11.4 | 98.6 | 98.6 | 98.6 | 13.3 | 8 |
| Week 32 | 13.2 | 93.2 | 100 | 96.5 | 15.6 | 8.7 |
| Week 48 | 17.6 | 91.5 | 98.5 | 94.9 | 13.3 | 26.1 |
| Day 1 Pre-infusion | 7.1 | 11.3 | 3 | 7.2 | 11.4 | 0 |
| Day 1 Post-infusion | 22.9 | 87 | 91.2 | 89.1 | 20.9 | 25.9 |
| Day 15 Pre-infusion | 7.4 | 100 | 98.6 | 99.3 | 9.3 | 4 |
| Day 15 Post-infusion | 17.9 | 100 | 100 | 100 | 21.4 | 12 |
| Week 16 Pre-infusion | 10.4 | 98.5 | 98.5 | 98.5 | 11.6 | 8.3 |
| Week 16 Post-infusion | 41 | 100 | 100 | 100 | 32.5 | 57.1 |
| Week 32 Pre-infusion | 8.3 | 95.2 | 100 | 97.6 | 10.3 | 4.8 |
| Week 32 Post-infusion | 35 | 100 | 100 | 100 | 26.3 | 50 |
CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. \<LLN = 80 cells/uL.
| Percentage of Participants | Placebo + SOC | OCR 400 mg + SOC | OCR 1000 mg + SOC | OCR + SOC | Placebo-Mycophenolate Mofetil (MMF) | Placebo-Euro Lupus (EL) |
|---|---|---|---|---|---|---|
| Baseline | 27.1 | 36.6 | 33.3 | 35 | 29.5 | 23.1 |
| Day 15 | 28.8 | 100 | 100 | 100 | 30 | 26.9 |
| Week 4 | 39.7 | 100 | 100 | 100 | 39 | 40.7 |
| Week 16 | 57.1 | 100 | 100 | 100 | 48.9 | 72 |
| Week 32 | 52.9 | 97.3 | 100 | 98.6 | 35.6 | 87 |
| Week 48 | 51.5 | 97.2 | 100 | 98.5 | 37.8 | 78.3 |
| Day 1 Pre-infusion | 27.1 | 36.6 | 32.8 | 34.8 | 29.5 | 23.1 |
| Day 1 Post-infusion | 55.7 | 97.1 | 100 | 98.5 | .5 | 59.3 |
| Day 15 Pre-infusion | 30.0 | 100 | 100 | 100 | 32.6 | 28 |
| Day 15 Post-infusion | 58.2 | 100 | 100 | 100 | 52.4 | 68 |
| Week 16 Pre-infusion | 56.7 | 100 | 100 | 100 | 48.8 | 70.8 |
| Week 16 Post-infusion | 80.3 | 100 | 100 | 100 | 72.5 | 95.2 |
| Week 32 Pre-infusion | 50 | 98.4 | 100 | 99.2 | 30.8 | 85.7 |
| Week 32 Post-infusion | 88.3 | 100 | 100 | 100 | 84.2 | 95.5 |
A major clinical response was defined as British Isles Lupus Assessment Group (BILAG) C scores or better at Week 24 without developing any new A or two new B scores up to Week 24 and maintenance of this response without developing a moderate or severe flare between Week 24 and Week 48. A partial clinical response was defined as BILAG C scores or better at Week 24 and maintaining this response without developing a flare for 16 consecutive weeks. The BILAG is an organ-specific 86-question assessment based on the principle of the doctor's intent to treat, which requires an assessment of improved (1), the same (2), worse (3), or new (4) over the last month. Within each organ system, multiple manifestations and laboratory tests are combined into a single score for that organ. The resulting scores for each organ can be A through E, where A is very active disease, B is moderate activity, C is mild stable disease, D is resolved activity, and E indicates the organ was never involved.
No measurements were reported for this outcome.
Collected over Baseline up to 19 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + SOC | 6/125 (4.8%) | 36/125 (28.8%) | 96/125 (76.8%) |
| OCR 1000 mg + SOC | 6/127 (4.7%) | 38/127 (29.9%) | 91/127 (71.7%) |
| OCR 400 mg + SOC | 3/126 (2.4%) | 53/126 (42.1%) | 101/126 (80.2%) |
| Event | Placebo + SOC | OCR 1000 mg + SOC | OCR 400 mg + SOC |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/125 | 8/127 | 4/126 |
| CellulitisInfections and infestations | 1/125 | 2/127 | 5/126 |
| NeutropeniaBlood and lymphatic system disorders | 1/125 | 5/127 | 2/126 |
| Urinary Tract InfectionInfections and infestations | 1/125 | 2/127 | 4/126 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 3/125 | 2/127 | 3/126 |
| ErysipelasInfections and infestations | 3/125 | 0/127 | 0/126 |
| AnaemiaBlood and lymphatic system disorders | 1/125 | 0/127 | 3/126 |
| AgranulocytosisBlood and lymphatic system disorders | 0/125 | 3/127 | 1/126 |
| Herpes zosterInfections and infestations | 0/125 | 3/127 | 1/126 |
| Chest painGeneral disorders | 2/125 | 0/127 | 0/126 |
| Event | Placebo + SOC | OCR 1000 mg + SOC | OCR 400 mg + SOC |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 22/125 | 32/127 | 26/126 |
| Urinary tract infectionInfections and infestations | 13/125 | 18/127 | 24/126 |
| Upper respiratory tract infectionInfections and infestations | 19/125 | 23/127 | 22/126 |
| LeukopeniaBlood and lymphatic system disorders | 7/125 | 12/127 | 18/126 |
| NasopharyngitisInfections and infestations | 16/125 | 13/127 | 17/126 |
| Infusion related reactionInjury, poisoning and procedural complications | 11/125 | 17/127 | 14/126 |
| NeutropeniaBlood and lymphatic system disorders | 6/125 | 7/127 | 15/126 |
| HeadacheNervous system disorders | 11/125 | 11/127 | 15/126 |
| BronchitisInfections and infestations | 10/125 | 10/127 | 14/126 |
| AnaemiaBlood and lymphatic system disorders | 5/125 | 7/127 | 13/126 |
| Age, Continuous(Years) | OCR 400 mg + SOC | OCR 1000 mg + SOC | Placebo + SOC | Total |
|---|---|---|---|---|
| Mean | 31.9 ± 10.2 | 30.6 ± 8.9 | 31.3 ± 9.9 | 31.3 ± 9.7 |
| Sex: Female, Male(Participants) | OCR 400 mg + SOC | OCR 1000 mg + SOC | Placebo + SOC | Total |
|---|---|---|---|---|
| Female | 115 | 110 | 107 | 332 |
| Male | 12 | 18 | 19 | 49 |
| Race (NIH/OMB)(Participants) | OCR 400 mg + SOC | OCR 1000 mg + SOC | Placebo + SOC | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 17 | 15 | 17 | 49 |
| Asian | 39 | 27 | 35 | 101 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 7 | 5 | 19 |
| White | 55 | 67 | 58 | 180 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 12 | 11 | 32 |
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
No publications or documents are linked to this record.
Ran from Feb 2008 to primary completion in Oct 2009, 20 months.
Results were first posted in Dec 2020, 11 years 2 months after primary completion. A results delay was requested in Mar 2016.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab